02:02 , Jun 9, 2018 |  BioCentury  |  Product Development

POC for cytokines

A body of clinical evidence is emerging that two different approaches to immune-stimulating cytokine therapies could increase efficacy of PD-1 inhibitors in both hot and cold tumors. Oncologists who spoke to BioCentury said, taken together,...
21:14 , Dec 14, 2017 |  BC Innovations  |  Emerging Company Profile

Backpacks for CARs

Torque Therapeutics Inc. is making “backpacks” for immune cell therapies that release immune stimulatory molecules at particular doses and locations to boost the cells’ activity without risking systemic exposure. The technology could augment the success...
04:21 , Dec 9, 2017 |  BioCentury  |  Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
20:15 , Jul 7, 2017 |  BC Week In Review  |  Company News

NantWorks acquires Altor BioScience

The NantCell immuno-oncology subsidiary of NantWorks LLC (Los Angeles, Calif.) will acquire Altor BioScience Corp. (Miramar, Fla.) for an undisclosed sum. NantCell said for each share of Altor held, shareholders will receive either $2 in...
22:01 , Apr 7, 2017 |  BioCentury  |  Finance

Combo quest

By leading Viracta Therapeutics Inc. ’s series B round and forging a partnership for its lead HDAC inhibitor last week, NantKwest Inc. (NASDAQ:NK) took another step toward bolstering its natural killer cell therapy arsenal. Wicklow...
04:27 , Jan 27, 2017 |  BC Week In Review  |  Clinical News

Allogeneic aNK cells: Preliminary Ph II QUILT-3.009 data

Preliminary data from 3 patients with unresectable stage IIIB or IV MCC in the open-label, U.S. Phase II QUILT-3.009 trial showed that 2x10 9 IV aNK cells/m 2 for 2 consecutive days every 2 weeks...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Company News

Altor BioScience, NantKwest deal

Altor and NantKwest partnered to co-develop cancer therapies using Altor’s ALT-803 and ALT-801 in combination with NantKwest’s natural killer (NK) cell therapy platforms. ALT-803, an IL-15 mutant agonist complexed to an Fc fusion protein of...
01:39 , Jan 13, 2016 |  BC Extra  |  Politics & Policy

Coalition aims for cancer MoonShot

Stakeholders including biopharma companies, academic research centers, community oncologists, payer Independence Blue Cross (Philadelphia, Pa.) and Bank of America Corp. (NYSE:BAC) launched the MoonShot 2020 initiative to test combination therapies in immuno-oncology. The initiative said...
07:00 , Jul 20, 2015 |  BC Week In Review  |  Clinical News

ALT-801: Phase Ib/II data

Data from 34 chemotherapy-refractory patients in the dose-escalation and expansion stages of an open-label, U.S. Phase Ib/II trial showed that 0.06 mg/kg IV ALT-801 plus gemcitabine with or without cisplatin led to an ORR of...
07:00 , May 4, 2015 |  BioCentury  |  Emerging Company Profile

Adding to immune function

Admune Therapeutics LLC is developing a heterodimeric complex of IL-15 to boost the immune system's response to cancer immunotherapies by increasing the number of antitumor lymphocytes overall and in the vicinity of tumors. Tumors' responses...